NUE
58
3
EXR
37
6
HBI
64
5
OMC
53
-2
VLO
62
3
ORCL
29
4
PNC
63
2
WAT
57
2
WHR
48
9
DTE
54
-2
ADM
45
-2
SE
52
5
SYK
48
-3
KEY
57
2
BAX
38
2
AVGO
17
5
SCHW
52
-3
DG
53
2
TGT
43
4
DLTR
48
-10
NUE
58
3
EXR
37
6
HBI
64
5
OMC
53
-2
VLO
62
3
ORCL
29
4
PNC
63
2
WAT
57
2
WHR
48
9
DTE
54
-2
ADM
45
-2
SE
52
5
SYK
48
-3
KEY
57
2
BAX
38
2
AVGO
17
5
SCHW
52
-3
DG
53
2
TGT
43
4
DLTR
48
-10
Financhill
Back

Tarsus Pharmaceuticals, Inc. 10K Form

Buy
61

TARS
Tarsus Pharmaceuticals, Inc.

Last Price:
$72.88
Seasonality Move:
18.73%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TARS News And Ratings

See the #1 stock for the next 7 days that we like better than TARS

TARS Financial Statistics

Sales & Book Value

Annual Sales: $183M
Cash Flow: $16.3M
Price / Cash Flow: 0
Annual Sales: $7.89
Price / Book: 9.24

Profitability

EPS (TTM): -2.01340
Net Income (TTM): $-81.2M
Gross Margin: $170.1M
Return on Equity: -27.56%
Return on Assets: -17.77%

Tarsus Pharmaceuticals, Inc. Earnings Forecast

Key Tarsus Pharmaceuticals, Inc. Financial Ratios

  • The Gross Profit Margin over the past 7 years for TARS is 92.99%.
  • The Selling, General & Administrative Expenses for TARS have been equal to 129.71% of Gross Profit Margin.
  • The Research & Development expenses have been 29.18% of Revenue.
  • The Net Earning history of TARS is -63.16% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 2 years.

Tarsus Pharmaceuticals, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: TARS
Website: tarsusrx.com

Debt

Debt-to-Equity Ratio: 0.25
Current Ratio: 4.29
Quick Ratio: 4.05

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 97.23

TARS Technical Analysis vs Fundamental Analysis

Buy
61
Tarsus Pharmaceuticals, Inc. (TARS) is a Buy

Is Tarsus Pharmaceuticals, Inc. a Buy or a Sell?